Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.52 |
| ▸ | SRC | P12931 | 9/20 | 0.51 |
| ▸ | ABL1 | P00519 | 7/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.49 |
| ▸ | PRKDC | P78527 | 2/20 | 0.49 |
| ▸ | ATR | Q13535 | 2/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.46 |
| ▸ | PRKD2 | Q9BZL6 | 5/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.46 |
| ▸ | FYN | P06241 | 4/20 | 0.46 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.46 |
| ▸ | CSK | P41240 | 3/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12551781 | 0.80 | RET (0.58) | RETSRCABL1PIK3CDPIK3CA | |
| SCHEMBL13019867 | 0.78 | RET (0.57) | RETSRCABL1PIK3CDPIK3CA | |
| SCHEMBL16655488 | 0.73 | ATR (0.59) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL13147582 | 0.72 | RET (0.50) | RETSRCABL1PIK3CDPIK3CA | |
| SCHEMBL30387689 | 0.72 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL16655772 | 0.71 | ATR (0.59) | RETPIK3CDATRBTK | |
| SCHEMBL19763994 | 0.68 | RET (1.00) | RETSRCABL1PIK3CDPIK3CA | |
| SCHEMBL409031 | 0.68 | SRC (1.00) | RETSRCABL1PIK3CDPIK3CA | |
| SCHEMBL13019650 | 0.68 | SRC (0.64) | RETSRCABL1PIK3CDPIK3CA | |
| SCHEMBL23471491 | 0.67 | RET (0.55) | RETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230111917-A1 | KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| EP-2551270-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2019-06-12 | — | — | EP | disclosed |
| US-8642604-B2 | Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2004654-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2551270-A2 | PYRAZOLOPYRMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS | The Regents of The University of California (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20110301144-A1 | Kinase Antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | US | disclosed |
| US-20100009963-A1 | KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-01-14 | — | — | US | disclosed |
| US-7585868-B2 | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-09-08 | — | — | US | disclosed |
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | MTOR, PI4KA, PIK3CA | RET 295/4885SRC 218/4885ABL1 225/4885 |
| US-20230111917-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | RET 289/4885SRC 131/4885ABL1 137/4885 |
| US-20100009963-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | RET 289/4885SRC 131/4885ABL1 137/4885 |
| US-20110301144-A1 | Kinase Antagonists | MTOR, RPS6KA3, AKT3 | RET 289/4885SRC 131/4885ABL1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.